Skip Navigation
Skip to contents

ACC : Acute and Critical Care

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
4 "cancer"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Rapid response system
Utilization of a rapid response team and associated outcomes in patients with malignancy
Jongmin Lee, Woo Ho Ban, Sei Won Kim, Eun Young Kim, Mi Ra Han, Seok Chan Kim
Acute Crit Care. 2020;35(1):16-23.   Published online February 29, 2020
DOI: https://doi.org/10.4266/acc.2019.00675
  • 5,160 View
  • 133 Download
  • 3 Web of Science
  • 6 Crossref
AbstractAbstract PDF
Background
Recent advances in diagnosis and treatment have improved long-term outcomes in cancer patients. As a result, the requirement for a rapid response team (RRT) for cancer patients is also increasing. This study aimed to analyze utilization of an RRT and the associations between related factors and mortality in a population of cancer patients. Methods: This retrospective cohort study included hospitalized patients at a single academic medical center in Seoul, Korea, who required RRT activation during a 6-year period from June 2013 to December 2018. Results: Overall, 164 of the 457 patients who met the above criteria were cancer patients, and they had a significantly higher Charlson comorbidity score than the non-cancer patients (5.0 vs. 7.0, P<0.001). A significantly larger proportion of cancer patients required intensive care unit transfer (51.8% vs. 41.0%, P=0.032). Cancer patients also had significantly higher in-hospital mortality compared with other patients (39.6% vs. 10.9%, P<0.001). Furthermore, presence of cancer was independently associated with in-hospital mortality (adjusted odds ratio [OR], 2.09; 95% confidence interval [CI], 1.11 to 3.93). Among cancer patients, higher Acute Physiology and Chronic Health Evaluation (APACHE) II at the time of RRT activation was significantly associated with in-hospital mortality regardless of malignancy (adjusted OR, 1.08; 95% CI, 1.01 to 1.15). Conclusions: Cancer patients requiring RRT activation have significantly higher rates of inhospital mortality than patients not using RRT. Higher severity score at the time of RRT activation in patients with malignancy was significantly associated with in-hospital mortality.

Citations

Citations to this article as recorded by  
  • Intensivmedizinisches Kontinuum in der Versorgung von Krebskranken
    Catherina Lück
    InFo Hämatologie + Onkologie.2023; 26(5): 10.     CrossRef
  • Characteristics and outcomes of patients screened by rapid response team who transferred to the intensive care unit
    Song-I. Lee, Jeong Suk Koh, Yoon Joo Kim, Da Hyun Kang, Jeong Eun Lee
    BMC Emergency Medicine.2022;[Epub]     CrossRef
  • Characteristics and Prognosis of Hospitalized Patients at High Risk of Deterioration Identified by the Rapid Response System: a Multicenter Cohort Study
    Sang Hyuk Kim, Ji Young Hong, Youlim Kim
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Novel Adaptive T-Cell Oncological Treatments Lead to New Challenges for Medical Emergency Teams: A 2-Year Experience From a Tertiary-Care Hospital in Switzerland
    Anna Sarah Messmer, Yok-Ai Que, Christoph Schankin, Yara Banz, Ulrike Bacher, Urban Novak, Thomas Pabst
    Critical Care Explorations.2021; 3(10): e0552.     CrossRef
  • Outcomes of second-tier rapid response activations in a tertiary referral hospital: A prospective observational study
    Ken Junyang Goh, Hui Zhong Chai, Lit Soo Ng, Joanna Phone Ko, Deshawn Chong Xuan Tan, Hui Li Tan, Constance Wei-Shan Teo, Ghee Chee Phua, Qiao Li Tan
    Annals of the Academy of Medicine, Singapore.2021; 50(11): 838.     CrossRef
  • Effectiveness of Rapid Response Team on In-hospital Mortality in Patients with Hematologic Malignancy
    So-Jung Park, Sang-Bum Hong, Chae-Man Lim, Youn-Suck Koh, Jin-Won Huh
    Quality Improvement in Health Care.2021; 27(2): 18.     CrossRef
Hematology
Characteristics and Clinical Outcomes of Critically Ill Cancer Patients Admitted to Korean Intensive Care Units
Soo Jin Na, Tae Sun Ha, Younsuck Koh, Gee Young Suh, Shin Ok Koh, Chae-Man Lim, Won-Il Choi, Young-Joo Lee, Seok Chan Kim, Gyu Rak Chon, Je Hyeong Kim, Jae Yeol Kim, Jaemin Lim, Sunghoon Park, Ho Cheol Kim, Jin Hwa Lee, Ji Hyun Lee, Jisook Park, Juhee Cho, Kyeongman Jeon
Acute Crit Care. 2018;33(3):121-129.   Published online August 31, 2018
DOI: https://doi.org/10.4266/acc.2018.00143
  • 7,875 View
  • 272 Download
  • 5 Web of Science
  • 7 Crossref
AbstractAbstract PDF
Background
The objective of this study was to investigate the characteristics and clinical outcomes of critically ill cancer patients admitted to intensive care units (ICUs) in Korea.
Methods
This was a retrospective cohort study that analyzed prospective collected data from the Validation of Simplified Acute Physiology Score 3 (SAPS3) in Korean ICU (VSKI) study, which is a nationwide, multicenter, and prospective study that considered 5,063 patients from 22 ICUs in Korea over a period of 7 months. Among them, patients older than 18 years of age who were diagnosed with solid or hematologic malignancies prior to admission to the ICU were included in the present study.
Results
During the study period, a total of 1,762 cancer patients were admitted to the ICUs and 833 of them were deemed eligible for analysis. Six hundred fifty-eight (79%) had solid tumors and 175 (21%) had hematologic malignancies, respectively. Respiratory problems (30.1%) was the most common reason leading to ICU admission. Patients with hematologic malignancies had higher Sequential Organ Failure Assessment (12 vs. 8, P<0.001) and SAPS3 (71 vs. 69, P<0.001) values and were more likely to be associated with chemotherapy, steroid therapy, and immunocompromised status versus patients with solid tumors. The use of inotropes/ vasopressors, mechanical ventilation, and/or continuous renal replacement therapy was more frequently required in hematologic malignancy patients. Mortality rates in the ICU (41.7% vs. 24.6%, P<0.001) and hospital (53.1% vs. 38.6%, P=0.002) were higher in hematologic malignancy patients than in solid tumor patients.
Conclusions
Cancer patients accounted for one-third of all patients admitted to the studied ICUs in Korea. Clinical characteristics were different according to the type of malignancy. Patients with hematologic malignancies had a worse prognosis than did patients with solid tumor.

Citations

Citations to this article as recorded by  
  • Outcomes of Acute Respiratory Failure in Patients With Cancer in the United States
    Kiyan Heybati, Jiawen Deng, Archis Bhandarkar, Fangwen Zhou, Cameron Zamanian, Namrata Arya, Mohamad Bydon, Philippe R. Bauer, Ognjen Gajic, Allan J. Walkey, Hemang Yadav
    Mayo Clinic Proceedings.2024;[Epub]     CrossRef
  • Predictors of ICU mortality in patients with hemoblastosis and infectious complications
    A.V. Lyanguzov, A.S. Luchinin, S.V. Ignatyev, I.V. Paramonov
    Anesteziologiya i reanimatologiya.2023; (1): 33.     CrossRef
  • Effect of the underlying malignancy on critically ill septic patient's outcome
    Man‐Yee Man, Hoi‐Ping Shum, Sin‐Man Lam, Jacky Li, Wing‐Wa Yan, Mei‐Wan Yeung
    Asia-Pacific Journal of Clinical Oncology.2022; 18(4): 473.     CrossRef
  • Impacts of Corticosteroid Therapy at Acute Stage of Hospital-Onset Clostridioides difficile Infections
    Ching-Chi Lee, Jen-Chieh Lee, Chun-Wei Chiu, Pei-Jane Tsai, Wen-Chien Ko, Yuan-Pin Hung
    Infection and Drug Resistance.2022; Volume 15: 5387.     CrossRef
  • Hospital mortality and prognostic factors in critically ill patients with acute kidney injury and cancer undergoing continuous renal replacement therapy
    Da Woon Kim, Geum Suk Jang, Kyoung Suk Jung, Hyuk Jae Jung, Hyo Jin Kim, Harin Rhee, Eun Young Seong, Sang Heon Song
    Kidney Research and Clinical Practice.2022; 41(6): 717.     CrossRef
  • A Systematic Review and Meta-Analysis Evaluating Geographical Variation in Outcomes of Cancer Patients Treated in ICUs
    Lama H. Nazer, Maria A. Lopez-Olivo, Anne Rain Brown, John A. Cuenca, Michael Sirimaturos, Khader Habash, Nada AlQadheeb, Heather May, Victoria Milano, Amy Taylor, Joseph L. Nates
    Critical Care Explorations.2022; 4(9): e0757.     CrossRef
  • Clinico-demographic and Outcome Predictors in Solid Tumor Patients with Unplanned Intensive Care Unit Admissions: An Observational Study
    Jigeeshu Divatia, Amit M Narkhede, Harish K Chaudhari, Ujwal Dhundi, Natesh Prabu Ravisankar, Satish Sarode
    Indian Journal of Critical Care Medicine.2021; 25(12): 1421.     CrossRef
Case Report
Pulmonary
Successful Treatment with Empirical Erlotinib in a Patient with Respiratory Failure Caused by Extensive Lung Adenocarcinoma
Suk Hyeon Jeong, Sang-Won Um, Hyun Lee, Kyeongman Jeon, Kyung Jong Lee, Gee Young Suh, Man Pyo Chung, Hojoong Kim, O Jung Kwon, Yoon La Choi
Korean J Crit Care Med. 2016;31(1):44-48.   Published online February 29, 2016
DOI: https://doi.org/10.4266/kjccm.2016.31.1.44
  • 5,249 View
  • 81 Download
  • 2 Crossref
AbstractAbstract PDF
We herein describe a 70-year-old woman who presented with respiratory failure due to extensive lung adenocarcinoma. Despite advanced disease, care in the intensive care unit with ventilator support was performed because she was a newly diagnosed patient and was considered to have the potential to recover after cancer treatment. Because prompt control of the cancer was needed to treat the respiratory failure, empirical treatment with an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor was initiated before confirmation of EGFR-mutant adenocarcinoma, and the patient was successfully treated. Later, EGFR-mutant adenocarcinoma was confirmed.

Citations

Citations to this article as recorded by  
  • Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report
    Shreya Bhatia, Manuel G. Cortez, Spencer Lessans, Wade T. Iams
    Oncotarget.2024; 15(1): 27.     CrossRef
  • Lung cancer with superior vena cava syndrome diagnosed by intravascular biopsy using EBUS-TBNA
    Daegeun Lee, Seong Mi Moon, Dongwuk Kim, Juwon Kim, Haseong Chang, Bumhee Yang, Suk Hyeon Jeong, Kyung Jong Lee
    Respiratory Medicine Case Reports.2016; 19: 177.     CrossRef
Original Article
Effect of the Neutrophil Elastase Inhibitor on Acute Lung Injury after Pulmonary Resection for Lung Cancer: A Preliminary Study
So Young Park, Sunghoon Park, Kyeongman Jeon, So Yeon Lim, Maeng Real Park, Sueah Kim, Jae Uk Song, Jhin Gook Kim, O Jung Kwon, Gee Young Suh
Korean J Crit Care Med. 2009;24(3):124-128.
DOI: https://doi.org/10.4266/kjccm.2009.24.3.124
  • 2,670 View
  • 22 Download
AbstractAbstract PDF
BACKGROUND
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the leading causes of death after lungresection. Neutrophil elastase is thought to be an important mediator in the pathogenesis of ALI. Sivelestat is a new neutrophil elastase inhibitor which may improve the outcome in patients with ALI/ARDS after lung resection. The objective of this study was to determine whether or not sivelestat can reduce mortality in patients with ALI after pulmonary resection for lung cancer.
METHODS
This study was a retrospective case-control study of twenty three patients who developed ALI/ARDS within seven days of lung resection for lung cancer. The control group (n = 12) received standard care, while the sivelestat group (n = 11) received a continuous infusion of sivelestat (0.2 mg/kg/hr) for seven days in addition to standard care.
RESULTS
There was no significant difference in the baseline characteristics between the control and sivelestat groups, except for heart rate. Six of twelve patients (50%) in the control group survived, while seven of twelve patients (64%) survived in the sivelestat group (p = 0.34). There was also no significant difference between the two groups in the progression to ARDS. In the sivelelestat group, survivors had lower APACHE II and SOFA scores than the patients in the control group.
CONCLUSIONS
There was no additional effect of a neutrophil elastase inhibitor in the treatment of ALI after pulmonary resection for lung cancer.

ACC : Acute and Critical Care